Amneal Pharmaceuticals
AMRX
164 hedge funds and large institutions have $1.55B invested in Amneal Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 60 increasing their positions, 50 reducing their positions, and 21 closing their positions.
515% more call options, than puts
Call options by funds: $1.31M | Put options by funds: $213K
20% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 50
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2% less capital invested
Capital invested by funds: $1.57B → $1.55B (-$27.3M)
2% less funds holding
Funds holding: 168 → 164 (-4)
6.69% less ownership
Funds ownership: 101.07% → 94.38% (-6.7%)
14% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.74M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$5.4M |
| 3 |
PFC
Phocas Financial Corp
Alameda,
California
|
+$4.97M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$3.17M |
| 5 |
Squarepoint
New York
|
+$2.86M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
-$31.8M |
| 2 |
HM
HealthCor Management
New York
|
-$28.7M |
| 3 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
-$21.8M |
| 4 |
BM
Bridger Management
New York
|
-$13.8M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$9.97M |
AMRX Hedge Fund Activity: Q1 2019 in Review
164 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Amneal Pharmaceuticals (AMRX) for Q1 2019, worth a combined $1.55B — down 1.7% from $1.57B a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of AMRX and 18 opened new positions — a net loss of 3 holders — while 50 trimmed existing stakes and 60 added.
The largest buyer was Vanguard Group, adding an estimated $5.74M. The largest seller was Viking Global Investors, exiting entirely with an estimated $31.8M sold.
- 164 institutional investors held Amneal Pharmaceuticals (AMRX) as of Q1 2019, down from 168 in Q4 2018.
- Funds reported $1.55B of Amneal Pharmaceuticals stock for Q1 2019, down 1.7% quarter-over-quarter.
- 18 funds opened new Amneal Pharmaceuticals positions in Q1 2019 and 21 closed out, a net change of -3 holders.
- The largest Amneal Pharmaceuticals buyer in Q1 2019 was Vanguard Group, an estimated $5.74M added.
- The largest Amneal Pharmaceuticals seller in Q1 2019 was Viking Global Investors, an estimated $31.8M sold.
Based on aggregated 13F filings for Q1 2019.